Steven Cohen Galmed Pharmaceuticals Ltd. Transaction History

Point72 Asset Management, L.P.

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2018 Feb 14, 2019	SELL	$6.59 - $14.47 $757,850 - $1.66 Million	-115,000 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$10.55 - $15.28 $5.39 Million - $7.81 Million	-511,000 Reduced 81.63%	115,000 $1.56 Million
Q2 2018 Aug 14, 2018	BUY	$5.04 - $17.96 $3.16 Million - $11.2 Million	626,000 New	626,000 $7.45 Million

Ticker GLMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,088,400
Market Cap $122M
Description
Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or t...

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.